Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Post time 2023-11-10 16:38:23

journal：Molecular Cancer Therapeutics

Authors：Daisuke Okajima; Satoru Yasuda; Takanori Maejima; Tsuyoshi Karibe; Ken Sakurai; Tetsuo Aida; Tadashi Toki; Junko Yamaguchi; Michiko Kitamura; Reiko Kamei; Tomomichi Fujitani; Tomoyo Honda; Tomoko Shibutani; Sumie Muramatsu; Takashi Nakada; Riki Goto; Shu Takahashi; Miki Yamaguchi; Hirofumi Hamada; Yutaka Noguchi; Masato Murakami; Yuki Abe; Toshinori Agatsuma

Published date：2021-12-1

DOI：10.1158/1535-7163.mct-21-0206

PDF link：https://aacrjournals.org/mct/art ... 29/3284044/2329.pdf

Article link：http://dx.doi.org/10.1158/1535-7163.mct-21-0206

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 2023-11-10 16:38:24

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-11-10 16:42:22

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-11-10 16:42:54

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-11-10 16:45:08

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AACR] Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells Copy